Embody review: pricing, fine print, and how it ranks

The price, in words

Embody is reported at tirzepatide at $99/mo — figures published by a competing comparison site (May 2026), not read on a provider pricing page we could capture. We list reported figures for completeness and exclude them from every ranking until source verification; our methodology treats an unverifiable low price as a question, not a winner.

What the fine print says

Every figure we hold for Embody is third-party (a competing comparison site, May 2026): $99/mo tirzepatide reported as all-in with consult and shipping, '$79' promo claims in banners. We could not capture any price on a provider pricing page at our capture date, so Embody is listed and reviewed but excluded from rankings until a source-verified figure exists. If accurate, $99 would undercut the entire verified field — which is exactly why an unverifiable claim can't be ranked.

Pharmacy & transparency

Price evidence: Third-party-reported. The dispensing pharmacy is not named publicly — the single most common transparency gap in this market. Ask which pharmacy fills the prescription, whether it is 503A or 503B, and whether a certificate of analysis is available; our pharmacy guide explains what each answer means.

Nearest alternatives at this price point

Shopping the immediate neighborhood, the closest verified substitutes are NexLife at $215 (flat at every dose, no membership, named pharmacy); Yucca Health at $258 (flat at every dose, no membership, prepaid to $225); IVIM Health at $278 (source-verified) — each linked matchup runs the full head-to-head arithmetic on this exact question.

State availability

Embody doesn't publish a state footprint we could capture — confirm your state at intake before anything else. State-by-state context, exceptions, and city coverage live in the 51-state cost guides.

Five questions before checkout

Whatever the marketing says, get answers to: (1) the current all-in monthly price, in writing, since no verifiable figure is published; (2) whether the price changes at any rung of the dose ladder, and the exact tier schedule; (3) which pharmacy, by name, fills the prescription — and whether it's 503A or 503B, licensed for your state, with a certificate of analysis available; (4) the cancellation mechanics — deadline relative to renewal, written-confirmation availability, and whether any membership cancels separately. A program that answers all five plainly has already told you most of what this review can.

Bottom line

Until Embody publishes verifiable pricing, treat any quoted figure as unconfirmed and get it in writing. For context, the verified market floor is $215/mo compounded tirzepatide and $133/mo compounded semaglutide, with brand Zepbound at $449/mo and Wegovy at $349/mo at maintenance.